Related Experiment Video
Updated: Dec 15, 2025
07:43
Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
19.3K
Decrease of Proliferative Potential and Vascular Density of Giant Prolactinoma in Patients Treated with Cabergoline.
Ludmila Astaf'eva1, Ludmila Shishkina1, Pavel Kalinin1
1N.N. Burdenko National Medical Research Center of Neurosurgery, Moscow, Russia.
Asian Journal of Neurosurgery
|July 14, 2020
Summary
Cabergoline effectively treats prolactinomas by reducing tumor size and prolactin levels. This study tracks its mechanism, showing reduced proliferation and angiogenesis over a decade.
Area of Science:
- Endocrinology
- Neurosurgery
- Oncology
Background:
- Prolactinomas are commonly treated with cabergoline, which typically reduces tumor size and normalizes prolactin levels.
- Understanding the in vivo mechanism of cabergoline's action on human prolactinoma cells is of significant interest.
Observation:
- A patient with a giant prolactinoma underwent surgical removal and subsequent cabergoline treatment.
- Tumor remnants were monitored via MRI and immunohistochemical analysis after surgery and treatment.
Findings:
- Cabergoline therapy led to persistent normoprolactinemia and restoration of function.
- The treatment resulted in a decreased proliferation index (Ki-67) and reduced tumor angiogenesis (CD31, CD34 expression).
- Tumor regression and absence of recurrence were observed over a 10-year follow-up period.
Implications:
- Cabergoline is a highly effective treatment for prolactinomas, inducing tumor regression.
- Its mechanism involves reducing tumor cell proliferation and angiogenesis.
- Long-term cabergoline therapy can lead to sustained remission and functional recovery in patients with prolactinomas.
